C

Caliway Biopharmaceuticals Co Ltd
TWSE:6919

Watchlist Manager
Caliway Biopharmaceuticals Co Ltd
TWSE:6919
Watchlist
Price: 154 TWD -2.84% Market Closed
Market Cap: 238.8B TWD

Wall Street
Price Targets

Price Targets Summary
Caliway Biopharmaceuticals Co Ltd

Wall Street analysts forecast Caliway Biopharmaceuticals Co Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Caliway Biopharmaceuticals Co Ltd is 244.8 TWD with a low forecast of 242.4 TWD and a high forecast of 252 TWD.

Lowest
Price Target
242.4 TWD
57% Upside
Average
Price Target
244.8 TWD
59% Upside
Highest
Price Target
252 TWD
64% Upside
Caliway Biopharmaceuticals Co Ltd Competitors:
Price Targets
1477
Ocumension Therapeutics
43% Upside
LLY
Eli Lilly and Co
3% Upside
CORT
Corcept Therapeutics Inc
71% Upside
216080
Jetema Co Ltd
50% Upside
300357
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
12% Upside
300558
Betta Pharmaceuticals Co Ltd
39% Upside

Revenue
Forecast

Revenue Estimate
Caliway Biopharmaceuticals Co Ltd

For the last 4 years the compound annual growth rate for Caliway Biopharmaceuticals Co Ltd's revenue is 44%. The projected CAGR for the next 3 years is 546%.

44%
Past Growth
546%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Operating Income
Forecast

Operating Income Estimate
Caliway Biopharmaceuticals Co Ltd

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Net Income
Forecast

Net Income Estimate
Caliway Biopharmaceuticals Co Ltd

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Caliway Biopharmaceuticals Co Ltd's stock price target?
Price Target
244.8 TWD

According to Wall Street analysts, the average 1-year price target for Caliway Biopharmaceuticals Co Ltd is 244.8 TWD with a low forecast of 242.4 TWD and a high forecast of 252 TWD.

What is Caliway Biopharmaceuticals Co Ltd's Revenue forecast?
Projected CAGR
546%

For the last 4 years the compound annual growth rate for Caliway Biopharmaceuticals Co Ltd's revenue is 44%. The projected CAGR for the next 3 years is 546%.

Back to Top